Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008

Published: 2009-06-23

Articles

Myelodysplastic syndromes

M Cazzola

https://doi.org/10.4081/hmr.v2i5.717

173

PDF: 94
- PDF
Organ damage and iron overload

E Angelucci, C Cogoni, M Pettinau, F Pilo, C Targhetta, F Zacchedu

https://doi.org/10.4081/hmr.v2i5.718

254

PDF: 1380
- PDF
Progress in the management of iron overload in erytrocyte disorders

MD Cappellini, E Cassinerio, L Zanaboni, G Fabio, P Pattoneri

https://doi.org/10.4081/hmr.v2i5.719

190

PDF: 1681
- PDF
Ph positive-leukemias

F Guilhot, L Roy, J Guilhot, PJ Saulnier, JM Gombert, A Turhan

https://doi.org/10.4081/hmr.v2i5.720

146

PDF: 147
- PDF
Thyrosin kinase inhibitors: nilotinib

F Castagnetti, F Palandri, G Gugliotta, A Poerio, M Amabile, S Soverini, G Martinelli, M Baccarani, G Rosti

https://doi.org/10.4081/hmr.v2i5.721

324

PDF: 415
- PDF
New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib

G Martinelli, I Iacobucci, D Cilloni, P Giannoulia, S Soverini, PP Piccaluga, C Papayannidis, S Paolini, C Terragna

https://doi.org/10.4081/hmr.v2i5.722

191

PDF: 192
- PDF
Peripheral T-cell lymphomas

SA Pileri, C Agostinelli, C Campidelli, F Bacci, E Sabattini, A Pileri Jr, PP Piccaluga

https://doi.org/10.4081/hmr.v2i5.723

210

PDF: 544
- PDF
Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma

M Duvic

https://doi.org/10.4081/hmr.v2i5.724

206

PDF: 2195
- PDF
A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

MG Bernengo, F Vanaclocha, M Duvic, T Kuzel, F Kerdel, L Pinter-Brown, A Bosly, C Okada, D Breneman, PL Zinzani, J Becker, L Hughey, M Ardaiz, J Zain, L Zhang

https://doi.org/10.4081/hmr.v2i5.725

165

PDF: 180
- PDF
Chronic lymphocytic leukemia

F Caligaris-Cappio

https://doi.org/10.4081/hmr.v2i5.727

167

PDF: 2465
- PDF
Monoclonal antibodies (update): CD20, rituximab

C Hagenbeek

https://doi.org/10.4081/hmr.v2i5.728

165

PDF: 108
- PDF
90Y-ibritumumab tiuxetan (Zevalin)

PL Zinzani

https://doi.org/10.4081/hmr.v2i5.729

194

PDF: 331
- PDF
Update of alemtuzumab in the treatment of chronic lymphocytic leukaemia

C Dearden

https://doi.org/10.4081/hmr.v2i5.731

158

PDF: 198
- PDF
Immunotherapy with epratuzumab in B-cell non-Hodgkin’s lymphoma

P Martin, D Goldenberg, JP Leonard

https://doi.org/10.4081/hmr.v2i5.732

129

PDF: 340
- PDF
New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin

S Amadori

https://doi.org/10.4081/hmr.v2i5.733

139

PDF: 534
- PDF
Update on galiximab: anti-CD80 monoclonal antibody

MS Czuczman

https://doi.org/10.4081/hmr.v2i5.734

187

PDF: 230
- PDF
CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin

JF DiJoseph, K Khandke, MM Dougher, DY Evans, DC Armellino, PR Hamann, NK Damle

https://doi.org/10.4081/hmr.v2i5.735

562

PDF: 2351
- PDF
Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma

C Assaf

https://doi.org/10.4081/hmr.v2i5.736

243

PDF: 314
- PDF
Monoclonal antibodies (novel): humax-CD20, ofatumumab

A Hagenbeek

https://doi.org/10.4081/hmr.v2i5.737

156

PDF: 192
- PDF
Lumiliximab in chronic lymphocytic leukemia

TS Lin

https://doi.org/10.4081/hmr.v2i5.738

155

PDF: 420
- PDF
Bevacizumab as an anti-VEGF strategy in lymphoma

SJ Horning

https://doi.org/10.4081/hmr.v2i5.739

250

PDF: 170
- PDF
Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams

BD Cheson

https://doi.org/10.4081/hmr.v2i5.741

158

PDF: 256
- PDF
Aurora kinase inhibitor: AS703569

A Gianella-Borradori

https://doi.org/10.4081/hmr.v2i5.742

184

PDF: 263
- PDF
From cell biology to therapy: lenalidomide in untreated multiple myeloma

A Palumbo, P Falco, F Gay, V Magarotto, F Patriarca, C Nozzoli, M Boccadoro

https://doi.org/10.4081/hmr.v2i5.744

159

PDF: 208
- PDF
HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells

PWHI Parren

https://doi.org/10.4081/hmr.v2i5.740

435

PDF: 577
- PDF
Pha-739358: a pan-aurora kinase inhibitor

R Paquette, N Shah, C Sawyers, G Martinelli, J Nicoll, M Chalukya

https://doi.org/10.4081/hmr.v2i5.743

209

Untitled (): 0

PDF: 403
- PDF
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma

P Richardson, T Hideshima, C Mitsiades, R Schlossman, J Laubach, I Ghobrial, N Raje, N Munshi, K Anderson

https://doi.org/10.4081/hmr.v2i5.745

147

PDF: 259
- PDF
Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas

A Dreyling

https://doi.org/10.4081/hmr.v2i5.749

330

PDF: 395
- PDF
From cell biology to therapy: forodesine

M Duvic

https://doi.org/10.4081/hmr.v2i5.746

329

PDF: 713
- PDF
Flavopiridol (alvocidib) in chronic lymphocytic leukemia

TS Lin, B Fischer, KA Blum, M Brooker-McEldowney, ME Moran, LA Andritsos, JM Flynn, MA Phelps, JT Dalton

https://doi.org/10.4081/hmr.v2i5.747

296

PDF: 775
- PDF
mTOR inhibitors for the treatment of lymphoma

TE Witzig

https://doi.org/10.4081/hmr.v2i5.748

172

PDF: 268
- PDF
Multiple myeloma

J San Miguel

https://doi.org/10.4081/hmr.v2i5.750

124

PDF: 91
- PDF
Proteasome inhibitors: bortezomib in multiple myeloma

M Cavo, MC Pallotti, L Pantani, A Petrucci, A Brioli, C Terragna, N Testoni, G Marzocchi, S Durante, M Ceccolini, G Perrone, P Tacchetti, E Zamagni, P Tosi, M Baccarani

https://doi.org/10.4081/hmr.v2i5.751

153

PDF: 196
- PDF
Bortezomib in lymphomas

A Goy

https://doi.org/10.4081/hmr.v2i5.752

160

PDF: 143
- PDF
Proteasome inhibitors: beyond NFKB inhibition alone and the emerging role of combination therapy in the treatment of multiple myeloma

P Richardson, C Mitsiades, J Laubach, C Conant, T Hideshima, D Chauhan, R Schlossman, I Ghobrial, N Munshi, KC Anderson

https://doi.org/10.4081/hmr.v2i5.753

377

PDF: 209
- PDF
Novel proteasome inhibitors

P Tosi, MC Pallotti, L Pantani, A Petrucci

https://doi.org/10.4081/hmr.v2i5.754

182

PDF: 312
- PDF
Decitabine in myeloid malignancies

HI Saba

https://doi.org/10.4081/hmr.v2i5.755

155

PDF: 755
- PDF
J-L. Harousseau Tipifarnib in hematologic malignancies

JL Harousseau

https://doi.org/10.4081/hmr.v2i5.756

142

PDF: 227
- PDF
Is there a role for immunotherapy in Hodgkin’s disease?

B Böll, A Engert

https://doi.org/10.4081/hmr.v2i5.757

127

PDF: 544
- PDF
New agents for the treatment of acute myeloid leukemia: midostaurin

S Amadori

https://doi.org/10.4081/hmr.v2i5.760

201

PDF: 860
- PDF
Lestaurtinib as a FLT3 inhibitor

AK Burnett

https://doi.org/10.4081/hmr.v2i5.761

134

PDF: 159

Untitled (): 0
- PDF